Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2001 Sep;56(9):721–726. doi: 10.1136/thorax.56.9.721

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations

M Dentener 1, E Creutzberg 1, A Schols 1, A Mantovani 1, V van`t 1, W Buurman 1, E Wouters 1
PMCID: PMC1746133  PMID: 11514694

Abstract

BACKGROUND—The aim of this study was to test the hypothesis that the chronic inflammatory process present in chronic obstructive pulmonary disease (COPD) is due to a defective endogenous anti-inflammatory mechanism.
METHODS—Systemic levels of the anti-inflammatory mediators soluble interleukin 1 receptor II (sIL-1RII), soluble tumour necrosis factor receptor p55 (sTNF-R55) and sTNF-R75, and of C reactive protein (CRP) and lipopolysaccharide binding protein (LBP) were analysed in 55 patients with stable COPD (median forced expiratory volume in one second (FEV1) 34% predicted (range 15-78)) and compared with levels in 23 control subjects. In addition, changes in these mediators were studied in 13 patients with COPD (median FEV1 34% predicted (range 19-51)) during the first 7 days in hospital with an exacerbation of the disease.
RESULTS—Patients with stable COPD were characterised by a systemic inflammatory process indicated by an increased leucocyte count (7.2 (4.7-16.4) v 4.8 (3.5-8.3) × 109/l), raised levels of CRP (11.8 (1.1-75.0) v 4.1 (0.6-75.0) µg/ml) and LBP (45.6 (8.1-200.0) v 27.9 (14.1-71.5) µg/ml), and moderate increases in both sTNF-Rs. In contrast, the sIL-1RII level did not differ between patients and controls (4.53 (2.09-7.60) v 4.63(3.80-5.93) ng/ml). During treatment of disease exacerbations, systemic levels of both CRP (at day 3) and LBP (at day 7) were significantly reduced compared with day 1, whereas sIL-1RII levels increased.
CONCLUSIONS—These data suggest an imbalance in systemic levels of pro- and anti-inflammatory mediators in patients with stable COPD. The increase in the anti-inflammatory mediator sIL-1RII during treatment of exacerbations may contribute to the clinical improvement.



Full Text

The Full Text of this article is available as a PDF (144.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., Gore S. M., Gardner M. J., Pocock S. J. Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) 1983 May 7;286(6376):1489–1493. doi: 10.1136/bmj.286.6376.1489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arend W. P., Malyak M., Smith M. F., Jr, Whisenand T. D., Slack J. L., Sims J. E., Giri J. G., Dower S. K. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol. 1994 Nov 15;153(10):4766–4774. [PubMed] [Google Scholar]
  3. Barnes P. J. Chronic obstructive pulmonary disease. N Engl J Med. 2000 Jul 27;343(4):269–280. doi: 10.1056/NEJM200007273430407. [DOI] [PubMed] [Google Scholar]
  4. Bhowmik A., Seemungal T. A., Sapsford R. J., Wedzicha J. A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000 Feb;55(2):114–120. doi: 10.1136/thorax.55.2.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bigda J., Holtmann H. TNF receptors--how they function and interact. Arch Immunol Ther Exp (Warsz) 1997;45(4):263–270. [PubMed] [Google Scholar]
  6. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J. G., Dower S. K., Sims J. E., Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993 Jul 23;261(5120):472–475. doi: 10.1126/science.8332913. [DOI] [PubMed] [Google Scholar]
  7. Colotta F., Saccani S., Giri J. G., Dower S. K., Sims J. E., Introna M., Mantovani A. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol. 1996 Apr 1;156(7):2534–2541. [PubMed] [Google Scholar]
  8. Coulter K. R., Wewers M. D., Lowe M. P., Knoell D. L. Extracellular regulation of interleukin (IL)-1beta through lung epithelial cells and defective IL-1 type II receptor expression. Am J Respir Cell Mol Biol. 1999 May;20(5):964–975. doi: 10.1165/ajrcmb.20.5.3458. [DOI] [PubMed] [Google Scholar]
  9. Dinarello C. A. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents. 1997 Jul-Sep;11(3):91–103. [PubMed] [Google Scholar]
  10. Fiorini G., Crespi S., Rinaldi M., Oberti E., Vigorelli R., Palmieri G. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother. 2000 Jun;54(5):274–278. doi: 10.1016/S0753-3322(00)80071-2. [DOI] [PubMed] [Google Scholar]
  11. Froon A. H., Dentener M. A., Greve J. W., Ramsay G., Buurman W. A. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995 May;171(5):1250–1257. doi: 10.1093/infdis/171.5.1250. [DOI] [PubMed] [Google Scholar]
  12. Giri J. G., Wells J., Dower S. K., McCall C. E., Guzman R. N., Slack J., Bird T. A., Shanebeck K., Grabstein K. H., Sims J. E. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol. 1994 Dec 15;153(12):5802–5809. [PubMed] [Google Scholar]
  13. Grant S., Aitchison T., Henderson E., Christie J., Zare S., McMurray J., Dargie H. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest. 1999 Nov;116(5):1208–1217. doi: 10.1378/chest.116.5.1208. [DOI] [PubMed] [Google Scholar]
  14. Hale K. K., Smith C. G., Baker S. L., Vanderslice R. W., Squires C. H., Gleason T. M., Tucker K. K., Kohno T., Russell D. A. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine. 1995 Jan;7(1):26–38. doi: 10.1006/cyto.1995.1004. [DOI] [PubMed] [Google Scholar]
  15. Hill A. T., Bayley D. L., Campbell E. J., Hill S. L., Stockley R. A. Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J. 2000 May;15(5):886–890. doi: 10.1034/j.1399-3003.2000.15e12.x. [DOI] [PubMed] [Google Scholar]
  16. Hill A. T., Campbell E. J., Bayley D. L., Hill S. L., Stockley R. A. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999 Dec;160(6):1968–1975. doi: 10.1164/ajrccm.160.6.9904097. [DOI] [PubMed] [Google Scholar]
  17. Hill A. T., Campbell E. J., Hill S. L., Bayley D. L., Stockley R. A. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000 Sep;109(4):288–295. doi: 10.1016/s0002-9343(00)00507-6. [DOI] [PubMed] [Google Scholar]
  18. Hill A., Gompertz S., Stockley R. Factors influencing airway inflammation in chronic obstructive pulmonary disease. Thorax. 2000 Nov;55(11):970–977. doi: 10.1136/thorax.55.11.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Keatings V. M., Collins P. D., Scott D. M., Barnes P. J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996 Feb;153(2):530–534. doi: 10.1164/ajrccm.153.2.8564092. [DOI] [PubMed] [Google Scholar]
  20. Leeuwenberg J. F., Jeunhomme T. M., Buurman W. A. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol. 1994 Apr 15;152(8):4036–4043. [PubMed] [Google Scholar]
  21. McMahan C. J., Slack J. L., Mosley B., Cosman D., Lupton S. D., Brunton L. L., Grubin C. E., Wignall J. M., Jenkins N. A., Brannan C. I. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 1991 Oct;10(10):2821–2832. doi: 10.1002/j.1460-2075.1991.tb07831.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Meagher L. C., Cousin J. M., Seckl J. R., Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol. 1996 Jun 1;156(11):4422–4428. [PubMed] [Google Scholar]
  23. Noguera A., Busquets X., Sauleda J., Villaverde J. M., MacNee W., Agustí A. G. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1664–1668. doi: 10.1164/ajrccm.158.5.9712092. [DOI] [PubMed] [Google Scholar]
  24. Orlando S., Sironi M., Bianchi G., Drummond A. H., Boraschi D., Yabes D., Mantovani A. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem. 1997 Dec 12;272(50):31764–31769. doi: 10.1074/jbc.272.50.31764. [DOI] [PubMed] [Google Scholar]
  25. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  26. Roland M., Bhowmik A., Sapsford R. J., Seemungal T. A., Jeffries D. J., Warner T. D., Wedzicha J. A. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001 Jan;56(1):30–35. doi: 10.1136/thorax.56.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Saetta M., Di Stefano A., Maestrelli P., Turato G., Ruggieri M. P., Roggeri A., Calcagni P., Mapp C. E., Ciaccia A., Fabbri L. M. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1646–1652. doi: 10.1164/ajrccm.150.6.7952628. [DOI] [PubMed] [Google Scholar]
  28. Schols A. M., Buurman W. A., Staal van den Brekel A. J., Dentener M. A., Wouters E. F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996 Aug;51(8):819–824. doi: 10.1136/thx.51.8.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Soler N., Ewig S., Torres A., Filella X., Gonzalez J., Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999 Nov;14(5):1015–1022. doi: 10.1183/09031936.99.14510159. [DOI] [PubMed] [Google Scholar]
  30. Takabatake N., Nakamura H., Abe S., Inoue S., Hino T., Saito H., Yuki H., Kato S., Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1179–1184. doi: 10.1164/ajrccm.161.4.9903022. [DOI] [PubMed] [Google Scholar]
  31. Wedzicha J. A., Seemungal T. A., MacCallum P. K., Paul E. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Meade T. W. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000 Aug;84(2):210–215. [PubMed] [Google Scholar]
  32. Yasuda N., Gotoh K., Minatoguchi S., Asano K., Nishigaki K., Nomura M., Ohno A., Watanabe M., Sano H., Kumada H. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med. 1998 Aug;92(8):993–999. doi: 10.1016/s0954-6111(98)90343-2. [DOI] [PubMed] [Google Scholar]
  33. van der Poll T., Jansen J., van Leenen D., von der Möhlen M., Levi M., ten Cate H., Gallati H., ten Cate J. W., van Deventer S. J. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis. 1993 Oct;168(4):955–960. doi: 10.1093/infdis/168.4.955. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES